Research article summary (published 30 May 2003):

Neurochemical and psychotropic effects of bupropion in healthy male subjects.

Full Abstract

Bupropion is a weak inhibitor of noradrenaline (NE) and dopamine (DA) reuptake and has no direct action on serotonin (5-HT) neuronal elements. In the rat brain, bupropion suppresses NE neuron firing activity via the activation of alpha(2)-adrenoceptors and increases that of 5-HT neurons through an indirect action on NE neurons. Twenty-five healthy young male volunteers, with no previous history of psychiatric disorders, were randomized to one of four 7-day regimens:
placebo, bupropion (150 mg) once daily, bupropion (150 mg) twice a day, and methylphenidate SR (20 mg daily). To assess the activity of the NE reuptake process, the blood pressure response to intravenous tyramine was determined. A decrease in the systolic pressure response to tyramine was considered evidence of NE reuptake inhibition. Effects on 5-HT reuptake were assessed by measuring whole blood 5-HT concentration, with a decrease serving as an index of 5-HT reuptake blockade. The Profile of Mood States (POMS) scale was used to assess behavioral and psychological changes. Neither bupropion nor methylphenidate altered the tyramine pressor response, in contrast to previous data that demonstrated decreases were obtained with NE reuptake inhibitors. Neither drug modified 5-HT concentrations. However, POMS scores revealed that bupropion at a dosage of 150 mg/day increased composedness, agreeability, and energy, whereas 300 mg/day improved only attention. In contrast, methylphenidate improved only energy. These data provide no evidence that bupropion acts as an inhibitor of NE or 5-HT reuptake in healthy humans. Presumably it enhances synaptic availability of NE by increasing release. Yet, because its behavioral profile is different from that of methylphenidate, it may not share all the biochemical properties of psychostimulants.

Learn Faster Today      Improve your study skills

Author information

Author/s: Gobbi, Gabriella (G); Slater, Susan (S); Boucher, Nathalie (N); Debonnel, Guy (G); Blier, Pierre (P);

Affiliation: Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montréal, Quebec, Canada.

Journal and publication information

Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal: Journal of clinical psychopharmacology (J Clin Psychopharmacol), published in United States. (Language: eng)

Reference: 2003-Jun; vol 23 (issue 3) : pp 233-9

Dates: Created 2003/06/26; Completed 2003/10/23; Revised 2006/11/15;

PMID: 12826985, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adult Affect - drug effects; physiology Analysis of Variance Blood Pressure - drug effects; physiology Bupropion - pharmacology Carrier Proteins - antagonists & inhibitors; metabolism Double-Blind Method Humans Male

Membrane Glycoproteins - antagonists & inhibitors; metabolism Membrane Transport Proteins Nerve Tissue Proteins Neuropsychological Tests - statistics & numerical data Norepinephrine Plasma Membrane Transport Proteins Psychotropic Drugs - pharmacology Serotonin - blood Serotonin Plasma Membrane Transport Proteins Symporters - antagonists & inhibitors; metabolism

Associated Chemicals: Carrier Proteins (0) ; Membrane Glycoproteins (0) ; Membrane Transport Proteins (0) ; Nerve Tissue Proteins (0) ; Norepinephrine Plasma Membrane Transport Proteins (0) ; Psychotropic Drugs (0) ; SLC6A2 protein, human (0) ; SLC6A4 protein, human (0) ; Serotonin Plasma Membrane Transport Proteins (0) ; Symporters (0) ; Bupropion (34841-39-9) ; Serotonin (50-67-9)

Related articles

These are the highest related articles currently in the database:

• Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. 30 Aug 2004
• Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. 17 Jul 2002
• The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. 13 Mar 2005
• Role of dopamine in behavioral sensitization to ethanol in DBA/2J mice. 30 Jan 2005
• [Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)] 30 May 2004
• Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. 30 Aug 2002
• Dopamine transporter mediated release of dopamine: role of chloride. 30 Aug 1994
• Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. 30 Jan 1998
• Subjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting. 30 Mar 2004
• Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat. 29 Apr 2005

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.